• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    4/22/24 8:07:03 AM ET
    $ADIL
    $ANL
    $CNSP
    $CYTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. The company's market cap stands at $10.5 million.
    • NKGen Biotech (NASDAQ:NKGN) shares moved upwards by 32.0% to $1.46. The company's market cap stands at $33.2 million. The company's, Q4 earnings came out 4 days ago.
    • T2 Biosystems (NASDAQ:TTOO) shares moved upwards by 18.91% to $3.52. The company's market cap stands at $30.9 million.
    • CNS Pharma (NASDAQ:CNSP) shares increased by 18.26% to $0.24. The company's market cap stands at $2.5 million.
    • Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 17.39% to $1.66. The market value of their outstanding shares is at $3.7 million.
    • Dermata Therapeutics (NASDAQ:DRMA) stock rose 11.18% to $0.36. The market value of their outstanding shares is at $2.3 million.

    Losers

    • Vaxxinity (NASDAQ:VAXX) stock declined by 61.3% to $0.18 during Monday's pre-market session. The company's market cap stands at $23.3 million.
    • Hepion Pharmaceuticals (NASDAQ:HEPA) stock declined by 37.82% to $1.25. The company's market cap stands at $6.8 million. The company's, Q4 earnings came out 4 days ago.
    • Adlai Nortye (NASDAQ:ANL) stock declined by 14.92% to $10.55. The company's market cap stands at $389.2 million.
    • Sunshine Biopharma (NASDAQ:SBFM) stock fell 13.89% to $1.52. The company's market cap stands at $1.5 million.
    • Revelation Biosciences (NASDAQ:REVB) shares declined by 13.12% to $1.95. The company's market cap stands at $3.1 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock decreased by 10.63% to $0.7. The company's market cap stands at $24.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $ANL
    $CNSP
    $CYTO

    CompanyDatePrice TargetRatingAnalyst
    Adlai Nortye Ltd.
    $ANL
    2/13/2026$16.00Neutral → Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    6/2/2025Buy → Neutral
    H.C. Wainwright
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Adlai Nortye Ltd.
    $ANL
    9/4/2024$9.00Buy
    H.C. Wainwright
    Adlai Nortye Ltd.
    $ANL
    10/24/2023$30.00Overweight
    Cantor Fitzgerald
    Vaxxinity Inc.
    $VAXX
    9/8/2023$7.00Outperform
    Robert W. Baird
    Vaxxinity Inc.
    $VAXX
    4/27/2022In-line
    Evercore ISI
    Hepion Pharmaceuticals Inc.
    $HEPA
    2/28/2022$3.50Overweight
    Cantor Fitzgerald
    More analyst ratings

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Adlai Nortye Ltd. upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Adlai Nortye Ltd. from Neutral to Buy and set a new price target of $16.00

    2/13/26 9:51:23 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adlai Nortye Ltd. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adlai Nortye Ltd. from Buy to Neutral

    6/2/25 11:24:27 AM ET
    $ANL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Adial Pharmaceuticals with a new price target

    Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00

    11/14/24 7:21:37 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

    GLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction and related disorders, today announced it has entered into a collaboration framework agreement with Molteni Farmaceutici ("Molteni") for a proposed exclusive partnership covering the commercialization of AD04 in Europe. The collaboration framework, which is subject to execution of a final definitive agreement, sets forth the strategic and financial parameters of the planned partnership, covering clinical, regulatory, manufacturing, and commercial terms. Under the framework

    3/3/26 8:17:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

    Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion's strategic shift to advancing clinically proven liquid biopsy tests under new leadership MORRISTOWN, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a precision diagnostics company, today announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA (ctRNA) to facilitate early diagnosis of hepatocellular carcinoma (HCC) in high-risk patients (cirrhosis). Most cases of liver cancer (75-90%) are HCC, and HCC is the sixth most common cancer w

    3/3/26 7:35:00 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

    GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on February 23, 2026, that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq determined that for the last 10 consecutive business days, from February 6 through February 20, 2026, the closing bid price of the Company's common stock has been at $1.00 per share or greater. The Company has now successfully

    2/24/26 9:00:00 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Faulkner Eric

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer O'Loughlin Steve

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:01:43 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    SEC Filings

    View All

    SEC Form 10-K filed by Adial Pharmaceuticals Inc

    10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/5/26 5:03:27 PM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adial Pharmaceuticals Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

    3/3/26 8:17:24 AM ET
    $ADIL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - Hepion Pharmaceuticals, Inc. (0001583771) (Filer)

    3/3/26 8:11:27 AM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    6/2/25 12:11:05 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

    4 - NKGen Biotech, Inc. (0001845459) (Issuer)

    5/7/25 4:05:15 PM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    3/5/24 4:05:35 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Financials

    Live finance-specific insights

    View All

    NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

    NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately $16.9 million paid to acquire 65% equity stake in recapitalized debt-free NKMax, with NKMax operations now expected to be funded through 2026.Funding provided by AlpineBrook Capital GP 1 Limited and NKGen CEO Dr. Paul Y. Song. SANTA ANA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK")

    9/9/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights Announced a new indication for Gemini in severe burn patients Released data showing Gemini priming attenuated inflammation in peripheral blood mononuclear cells Completed dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients "While we continue to expand the pipeline here at Revelation, we are excited to continue our collaboration with Vanderbilt and Dr. Bohannon in the area of severe bu

    5/8/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FDA Acceptance of Gemini IND Received net proceeds of $3.7 million from the exercise of warrants in December 2024 "We made significant progress at the end of last year and hope to continue that pace in 2025," said James

    3/6/25 4:15:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Leadership Updates

    Live Leadership Updates

    View All

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

    Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F. Tidmarsh, MD, PhD from the Company's Board of Directors. "The team at Revelation wholeheartedly thanks Dr. Tidmarsh for his guidance and support over the past 5 years," said James Rolke, Chief Executive Officer of Revelation. "While he will be missed, we wish him the best of luck in his newest endeavor." "The Revelation team is dedicated to developing innovative therapies to improve the clinical outcomes for patients in need," said Dr. Tidmarsh. "I thank them for their passio

    5/23/25 4:05:00 PM ET
    $REVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $ANL
    $CNSP
    $CYTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hepion Pharmaceuticals Inc.

    SC 13G/A - Hepion Pharmaceuticals, Inc. (0001583771) (Subject)

    11/14/24 4:07:59 PM ET
    $HEPA
    Biotechnology: Pharmaceutical Preparations
    Health Care